Ann: Appendix 4C and Quarterly Update, page-35

When FightMND comes to you with a bag of money and sites, PIs the calibre of Prof. Mathers and Rowe wanting to trial your drug for their patients you don’t push them to the back of the queue, I don’t think it was the wrong decision to run with the MND trial. We learnt from exploring the covid trial path that we needed phase 1 safety data for our newly formulated tablet to progress down the phase 2 path.
The phase 1/2 trial for MND has completed and given use valuable data now to look at the other applications, I recall Roger saying MPL will find its place, it’s niche in the market. The journey might be just beginning after the phase 1 data is released.